Novartis(NVS) - 2023 Q3 - Earnings Call Presentation

ianalumab - BAFF-R inhibitor Primary Outcome Measures | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------|---------------------------------------------|---------------------------|-----------------------------------------------------------|-----------------------------|-------| | Company overview Company overview | Financial review Financial review | Conclusions Conclusions | Appendix Appendix | References References | | | Innovation: Pipeline overview Inno ...